|
Medipal Holdings Corporation (7459.T) Avaliação DCF
JP | Healthcare | Medical - Distribution | JPX
|
- ✓ Totalmente Editável: Adapte-Se Às Suas Necessidades No Excel Ou Planilhas
- ✓ Design Profissional: Modelos Confiáveis E Padrão Da Indústria
- ✓ Pré-Construídos Para Uso Rápido E Eficiente
- ✓ Não É Necessária Experiência; Fácil De Seguir
MediPal Holdings Corporation (7459.T) Bundle
Procurando avaliar o valor intrínseco da Medipal Holdings Corporation? Nossa calculadora DCF (7459T) integra dados do mundo real com extensos recursos de personalização, permitindo refinar suas previsões e aprimorar suas opções de investimento.
Discounted Cash Flow (DCF) - (USD MM)
| Year | AY1 2019 |
AY2 2020 |
AY3 2021 |
AY4 2022 |
AY5 2023 |
FY1 2024 |
FY2 2025 |
FY3 2026 |
FY4 2027 |
FY5 2028 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 3,253,122.0 | 3,211,173.0 | 3,290,921.0 | 3,360,008.0 | 3,558,732.0 | 3,640,651.0 | 3,724,455.8 | 3,810,189.6 | 3,897,897.0 | 3,987,623.4 |
| Revenue Growth, % | 0 | -1.29 | 2.48 | 2.1 | 5.91 | 2.3 | 2.3 | 2.3 | 2.3 | 2.3 |
| EBITDA | 67,798.0 | 53,370.0 | 59,963.0 | 63,622.0 | 65,313.0 | 67,694.0 | 69,252.3 | 70,846.4 | 72,477.3 | 74,145.6 |
| EBITDA, % | 2.08 | 1.66 | 1.82 | 1.89 | 1.84 | 1.86 | 1.86 | 1.86 | 1.86 | 1.86 |
| Depreciation | 14,687.0 | 14,792.0 | 14,338.0 | 14,648.0 | 17,982.0 | 16,667.2 | 17,050.9 | 17,443.4 | 17,844.9 | 18,255.7 |
| Depreciation, % | 0.45147 | 0.46064 | 0.43568 | 0.43595 | 0.50529 | 0.45781 | 0.45781 | 0.45781 | 0.45781 | 0.45781 |
| EBIT | 53,111.0 | 38,578.0 | 45,625.0 | 48,974.0 | 47,331.0 | 51,026.8 | 52,201.4 | 53,403.1 | 54,632.4 | 55,889.9 |
| EBIT, % | 1.63 | 1.2 | 1.39 | 1.46 | 1.33 | 1.4 | 1.4 | 1.4 | 1.4 | 1.4 |
| Total Cash | 226,315.0 | 241,517.0 | 261,920.0 | 195,031.0 | 230,470.0 | 252,788.8 | 258,607.8 | 264,560.8 | 270,650.7 | 276,880.9 |
| Total Cash, percent | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 | .0 |
| Account Receivables | 688,683.0 | 701,778.0 | 710,993.0 | 729,314.0 | 824,471.0 | 797,318.0 | 815,671.6 | 834,447.7 | 853,656.0 | 873,306.4 |
| Account Receivables, % | 21.17 | 21.85 | 21.6 | 21.71 | 23.17 | 21.9 | 21.9 | 21.9 | 21.9 | 21.9 |
| Inventories | 151,122.0 | 155,593.0 | 159,279.0 | 169,562.0 | 172,030.0 | 176,289.5 | 180,347.5 | 184,499.0 | 188,746.0 | 193,090.8 |
| Inventories, % | 4.65 | 4.85 | 4.84 | 5.05 | 4.83 | 4.84 | 4.84 | 4.84 | 4.84 | 4.84 |
| Accounts Payable | 883,624.0 | 900,014.0 | 907,997.0 | 890,966.0 | 924,297.0 | 984,944.0 | 1,007,616.6 | 1,030,811.1 | 1,054,539.5 | 1,078,814.2 |
| Accounts Payable, % | 27.16 | 28.03 | 27.59 | 26.52 | 25.97 | 27.05 | 27.05 | 27.05 | 27.05 | 27.05 |
| Capital Expenditure | -27,352.0 | -15,668.0 | -18,877.0 | -13,504.0 | -19,395.0 | -20,746.1 | -21,223.6 | -21,712.2 | -22,212.0 | -22,723.3 |
| Capital Expenditure, % | -0.84079 | -0.48792 | -0.57361 | -0.4019 | -0.545 | -0.56984 | -0.56984 | -0.56984 | -0.56984 | -0.56984 |
| Tax Rate, % | 44.51 | 44.51 | 44.51 | 44.51 | 44.51 | 44.51 | 44.51 | 44.51 | 44.51 | 44.51 |
| EBITAT | 26,696.1 | 18,746.4 | 23,434.5 | 27,126.1 | 26,264.1 | 26,646.3 | 27,259.7 | 27,887.2 | 28,529.1 | 29,185.8 |
| Depreciation | ||||||||||
| Changes in Account Receivables | ||||||||||
| Changes in Inventories | ||||||||||
| Changes in Accounts Payable | ||||||||||
| Capital Expenditure | ||||||||||
| UFCF | 57,850.1 | 16,694.4 | 13,977.5 | -17,364.9 | -39,442.9 | 106,108.0 | 23,347.9 | 23,885.3 | 24,435.2 | 24,997.6 |
| WACC, % | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 | 4.97 |
| PV UFCF | ||||||||||
| SUM PV UFCF | 182,649.7 | |||||||||
| Long Term Growth Rate, % | 2.00 | |||||||||
| Free cash flow (T + 1) | 25,498 | |||||||||
| Terminal Value | 857,350 | |||||||||
| Present Terminal Value | 672,589 | |||||||||
| Enterprise Value | 855,238 | |||||||||
| Net Debt | -230,154 | |||||||||
| Equity Value | 1,085,392 | |||||||||
| Diluted Shares Outstanding, MM | 212 | |||||||||
| Equity Value Per Share | 5,125.00 |
What You Will Receive
- Authentic MediPal Data: Preloaded financial metrics – including revenue and EBIT – derived from actual and forecasted figures.
- Comprehensive Customization: Modify all essential parameters (yellow cells) such as WACC, growth rates, and tax percentages.
- Immediate Valuation Adjustments: Automatic recalculations to evaluate the effects of changes on MediPal’s fair value.
- Flexible Excel Template: Designed for easy modifications, scenario analyses, and in-depth forecasts.
- Efficient and Precise: Avoid the hassle of building models from the ground up while ensuring accuracy and adaptability.
Key Features
- Genuine MediPal Financials: Gain access to precise historical data and future forecasts pre-loaded into the system.
- Adjustable Forecast Parameters: Modify the yellow-highlighted cells for WACC, growth rates, and profit margins.
- Real-Time Calculations: Instant updates to DCF, Net Present Value (NPV), and cash flow assessments.
- User-Friendly Dashboard: Clear charts and summaries designed to help you visualize your valuation outcomes.
- Suitable for All Skill Levels: An easy-to-navigate framework crafted for investors, CFOs, and consultants alike.
How It Works
- Step 1: Download the prebuilt Excel template featuring MediPal Holdings Corporation’s (7459T) data.
- Step 2: Navigate through the pre-filled sheets to familiarize yourself with the essential metrics.
- Step 3: Modify forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
- Step 4: Instantly see the recalibrated results, including the intrinsic value of MediPal Holdings Corporation (7459T).
- Step 5: Use the output to make informed investment decisions or create comprehensive reports.
Why Opt for This Calculator?
- All-in-One Solution: Combines DCF, WACC, and financial ratio analyses for a comprehensive evaluation.
- Tailored Inputs: Modify the yellow-highlighted cells to explore different scenarios and outcomes.
- In-Depth Analysis: Automatically determines the intrinsic value and Net Present Value for MediPal Holdings Corporation (7459T).
- Preloaded Information: Features historical and forecasted data to provide precise starting points.
- High-Quality Standards: Perfect for financial analysts, investors, and business consultants seeking reliable insights.
Who Can Benefit from MediPal Holdings Corporation (7459T)?
- Investors: Make informed investment choices with a sophisticated valuation tool.
- Financial Analysts: Increase efficiency with a customizable pre-built DCF model.
- Consultants: Effortlessly tailor the template for client presentations or reports.
- Finance Enthusiasts: Enhance your knowledge of valuation methods through practical examples.
- Educators and Students: Utilize it as an effective learning resource in finance education.
Contents of the Template
- Pre-Filled Data: Features MediPal Holdings Corporation's (7459T) historical financial information and future projections.
- Discounted Cash Flow Model: An editable DCF valuation model complete with automatic calculations.
- Weighted Average Cost of Capital (WACC): A specific sheet for calculating WACC using custom inputs.
- Key Financial Ratios: Examine MediPal's (7459T) profitability, efficiency, and financial leverage.
- Customizable Inputs: Easily modify revenue growth rates, profit margins, and tax rates.
- Clear Dashboard: Visual representations and tables summarizing essential valuation results.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.